B7-33

2mg Vial

10mg Vial

2 September 2026Updated 2 September 2026

B7-33

Overview Research0 Mechanism Protocols Safety

Discussions

This is Premium content Premium

Create a free account, then upgrade to Premium or Lifetime to unlock the full research article, mechanism of action, results timeline, dosing protocol, and dose calculator for B7-33.

Create free account Member login

Full range of benefits for B7-33

Shown in preclinical models to reduce cardiac fibrosis and collagen deposition

Attenuates myofibroblast activation and differentiation in tissue injury models

Biased RXFP1 agonist preferentially activates ERK1/2 over cAMP signaling

May limit adverse cardiac remodeling after myocardial infarction in rodents

Reduces renal fibrosis in preclinical kidney injury studies

May decrease TGF-beta-driven profibrotic signaling pathways

Less vasodilatory effect than full-length relaxin, potentially lower hypotension risk

Supports matrix remodeling and reduced scar formation in animal studies

Single-chain design facilitates chemical synthesis and mechanistic study

This peptide's combination-safety and interaction data below always stays visible, regardless of membership.

Warning

Important information. The data compiled from scientific literature is provided for educational purposes. Dosage ranges reflect what is reported in studies and do not constitute a recommendation, prescription, or usage guidance. Health decisions should always be made with a qualified professional.

Peptide Interactions

// 16 known interactions

Synergistic(4)Compatible(4)Monitor(4)Avoid(4)

Not recommended for concurrent use

Nitrates (e.g., nitroglycerin)

Exercise caution because concomitant vasodilators including nitrates can cause profound symptomatic hypotension when combined with B7‑33’s vasodilatory actions.

Phosphodiesterase‑5 inhibitors (e.g., sildenafil)

Avoid or use with caution and close hemodynamic monitoring due to risk of marked hypotension from additive vasodilatory/cGMP‑mediated effects.

Pregnancy

Use in pregnancy should be avoided or carefully evaluated because B7‑33 acts on relaxin pathways that are active in pregnancy and fetal safety data are lacking.

Severe hypotension or volume depletion

Caution is advised in patients with baseline hypotension or significant volume depletion as B7‑33’s vasodilatory and hemodynamic effects may exacerbate instability.

All interaction categories

Synergistic (4)

Angiotensin‑converting enzyme inhibitors (e.g., enalapril): ACE inhibitors and B7‑33 may provide complementary antifibrotic and hemodynamic benefits through distinct but convergent pathways, potentially enhancing cardiac and renal remodeling outcomes.
Angiotensin receptor blockers (e.g., losartan): ARBs share antifibrotic and vasodilatory effects that can be additive with B7‑33, supporting combined use for cardiorenal protection under monitoring.
Mineralocorticoid receptor antagonists (e.g., spironolactone): MR antagonists reduce fibrosis and remodeling and may synergize with B7‑33's antifibrotic activity to improve structural cardiac and renal outcomes.
SGLT2 inhibitors (e.g., empagliflozin): SGLT2 inhibitors provide independent cardiorenal protective and antifibrotic effects that can complement B7‑33’s mechanisms to enhance overall organ protection.

Compatible (4)

Statins (e.g., atorvastatin): No expected pharmacokinetic interaction with B7‑33 and potential complementary cardiovascular risk reduction make statins compatible for co‑administration.
Metformin: Metformin has a neutral interaction profile with peptide therapeutics like B7‑33 and may be continued without specific dose adjustments.
Low‑dose aspirin: Low‑dose aspirin for antiplatelet prophylaxis has no known direct interaction with B7‑33 and is generally compatible under routine clinical care.
Levothyroxine: Thyroid hormone replacement is not expected to interact with proteolytically degraded peptides such as B7‑33 and can be co‑administered with routine monitoring of thyroid status.

Monitor (4)

Beta‑blockers (e.g., metoprolol): Monitor blood pressure and heart rate when combining beta‑blockers with B7‑33 because additive hemodynamic effects may necessitate dose adjustments.
Diuretics (loop and thiazide, e.g., furosemide, hydrochlorothiazide): Monitor volume status, blood pressure and electrolytes as combined vasodilatory and diuretic effects can increase risk of symptomatic hypotension and electrolyte disturbances.
ACE inhibitors/ARBs: When used together with B7‑33, monitor renal function and serum potassium because additive renal hemodynamic changes can affect glomerular filtration and potassium homeostasis.
Potassium supplements or potassium‑sparing agents: Monitor serum potassium closely if combined with B7‑33 plus MRAs or RAAS inhibitors due to increased risk of hyperkalaemia from overlapping effects on potassium balance.

Avoid (4)

Nitrates (e.g., nitroglycerin): Exercise caution because concomitant vasodilators including nitrates can cause profound symptomatic hypotension when combined with B7‑33’s vasodilatory actions.
Phosphodiesterase‑5 inhibitors (e.g., sildenafil): Avoid or use with caution and close hemodynamic monitoring due to risk of marked hypotension from additive vasodilatory/cGMP‑mediated effects.
Pregnancy: Use in pregnancy should be avoided or carefully evaluated because B7‑33 acts on relaxin pathways that are active in pregnancy and fetal safety data are lacking.
Severe hypotension or volume depletion: Caution is advised in patients with baseline hypotension or significant volume depletion as B7‑33’s vasodilatory and hemodynamic effects may exacerbate instability.